by Plus Therapeutics | Feb 11, 2025 | GBM, LM, PBC, Uncategorized
Celebrating Strength and Resilience: Patient Appreciation Month At Plus Therapeutics, we are honored to celebrate #PatientAppreciationMonth and recognize the incredible strength, resilience, and courage of patients facing cancer. 🧡 Every day, we are inspired by those...
by Plus Therapeutics | Feb 4, 2025 | GBM
New Clinical Trial Site Now Enrolling – OSUCCC-James Joins ReSPECT-GBM! We are excited to announce that The Ohio State University Comprehensive Cancer Center – James (OSUCCC – James) has joined our ReSPECT-GBM Clinical Trial as a new investigation site, with Principal...
by Plus Therapeutics | Feb 4, 2025 | GBM, LM, PBC, Uncategorized
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
by Plus Therapeutics | Feb 1, 2025 | GBM, LM, PBC, Uncategorized
A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...
by Plus Therapeutics | Jan 14, 2025 | GBM
ReSPECT-GBM Clinical Trial Update: Phase 2 Enrollment Now Open We are excited to announce that enrollment for the Phase 1 ReSPECT-GBM clinical trial is complete! We are actively enrolling patients for Phase 2 of the trial, which focuses on treating recurrent...
by Plus Therapeutics | Dec 19, 2024 | GBM
🎗️ Now Streaming: ReSPECT-GBM Patient Story – Jim’s Journey as a Recurrent Glioblastoma Survivor Watch Jim’s Inspiring Story Now on YouTube: Watch Jim’s Story Dr. Jim Stockand, a dedicated educator with a PhD in Physiology, has devoted the past 24 years to...
Recent Comments